Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 24;58(12):1719.
doi: 10.3390/medicina58121719.

Dinebra retroflexa Herbal Phytotherapy: A Simulation Study Based on Bleomycin-Induced Pulmonary Fibrosis Retraction Potential in Swiss Albino Rats

Atef A El-Hela  1 , Mostafa M Hegazy  1 , Hatem S Abbass  1   2 , Amal H Ahmed  3 , Marwa S Abu Bakr  3 , Rawah H Elkousy  3 , Adel Ehab Ibrahim  4   5 , Sami El Deeb  4   6 , Ossama M Sayed  7 , Enas S Gad  8   9
Affiliations

Dinebra retroflexa Herbal Phytotherapy: A Simulation Study Based on Bleomycin-Induced Pulmonary Fibrosis Retraction Potential in Swiss Albino Rats

Atef A El-Hela et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Fibrotic lung disease is one of the main complications of many medical conditions. Therefore, the use of anti-fibrotic agents may provide a chance to prevent, or at least modify, such complication. The aim of this study was to evaluate the protective pulmonary anti-fibrotic and anti-inflammatory effects of Dinebra retroflexa. Materials and methods: Dinebra retroflexa methanolic extract and its synthesized silver nanoparticles were tested on bleomycin-induced pulmonary fibrosis. Pulmonary fibrosis was induced by intratracheal instillation of bleomycin (5 mg/5 mL/kg-Saline) as a supposed model for induced lung fibrosis. The weed evaluation was performed by intratracheal instillation of Dinebra retroflexa methanolic extract and its silver nanoparticles (35 mg/100 mL/kg-DMSO, single dose). Results: The results showed that both Dinebra retroflexa methanolic extract and its silver nanoparticles had a significant pulmonary fibrosis retraction potential, with Ashcroft scores of three and one, respectively, and degrees of collagen deposition reduction of 33.8 and 46.1%, respectively. High-resolution UHPLC/Q-TOF-MS/MS metabolic profiling and colorimetrically polyphenolic quantification were performed for further confirmation and explanation of the represented effects. Such activity was believed to be due to the tentative identification of twenty-seven flavonoids and one phenolic acid along with a phenolic content of 57.8 mg/gm (gallic acid equivalent) and flavonoid content of 22.5 mg/gm (quercetin equivalent). Conclusion: Dinebra retroflexa may be considered as a promising anti-fibrotic agent for people at high risk of complicated lung fibrosis. The results proved that further clinical trials would be recommended to confirm the proposed findings.

Keywords: Dinebra retroflexa; UHPLC/QTOF-MS/MS; bleomycin; pulmonary fibrosis; silver nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
TEM images of Ag-NPs prepared by citrate reduction (a) and DRE reduction (b).
Figure 2
Figure 2
Effect of DRE and DRN on lung histopathology in BLM male Swiss albino rats (H&E × 100; image resolution 300 DPI).
Figure 3
Figure 3
Effect of DRE and DRN on collagen deposition in the lungs of BLM male Swiss albino rats (Masson Trichrome × 100; image resolution 300 DPI).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Noble P.W., Barkauskas C.E., Jiang D. Pulmonary fibrosis: Patterns and perpetrators. J. Clin. Investig. 2012;122:2756–2762. doi: 10.1172/JCI60323. - DOI - PMC - PubMed
    1. Sharaf Y.A., El Deeb S., Ibrahim A.E., Al-Harrasi A., Sayed R.A. Two Green Micellar HPLC and Mathematically Assisted UV Spectroscopic Methods for the Simultaneous Determination of Molnupiravir and Favipiravir as a Novel Combined COVID-19 Antiviral Regimen. Molecules. 2022;27:2330. doi: 10.3390/molecules27072330. - DOI - PMC - PubMed
    1. George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir. Med. 2020;8:807–815. doi: 10.1016/S2213-2600(20)30225-3. - DOI - PMC - PubMed
    1. White E.S., Thomas M., Stowasser S., Tetzlaff K. Challenges for Clinical Drug Development in Pulmonary Fibrosis. Front. Pharmacol. 2022;13:823085. doi: 10.3389/fphar.2022.823085. - DOI - PMC - PubMed
    1. Dudala S.S., Venkateswarulu T., Kancharla S.C., Kodali V.P., Babu D.J. A review on importance of bioactive compounds of medicinal plants in treating idiopathic pulmonary fibrosis (special emphasis on isoquinoline alkaloids) Futur. J. Pharm. Sci. 2021;7:156. doi: 10.1186/s43094-021-00304-5. - DOI